Dianthus Therapeutics (NASDAQ:DNTH – Get Free Report) and Phio Pharmaceuticals (NASDAQ:PHIO – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, profitability, valuation, earnings and analyst recommendations.
Analyst Recommendations
This is a summary of recent ratings for Dianthus Therapeutics and Phio Pharmaceuticals, as provided by MarketBeat.com.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Dianthus Therapeutics | 0 | 0 | 9 | 2 | 3.18 |
Phio Pharmaceuticals | 0 | 0 | 1 | 0 | 3.00 |
Dianthus Therapeutics currently has a consensus target price of $45.13, indicating a potential upside of 62.85%. Phio Pharmaceuticals has a consensus target price of $36.00, indicating a potential upside of 1,137.11%. Given Phio Pharmaceuticals’ higher possible upside, analysts plainly believe Phio Pharmaceuticals is more favorable than Dianthus Therapeutics.
Profitability
Net Margins | Return on Equity | Return on Assets | |
Dianthus Therapeutics | -1,376.42% | -21.03% | -20.18% |
Phio Pharmaceuticals | N/A | -142.68% | -111.75% |
Earnings and Valuation
This table compares Dianthus Therapeutics and Phio Pharmaceuticals”s gross revenue, earnings per share and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Dianthus Therapeutics | $2.83 million | 287.58 | -$43.56 million | ($5.54) | -5.00 |
Phio Pharmaceuticals | N/A | N/A | -$10.83 million | ($29.25) | -0.10 |
Phio Pharmaceuticals has lower revenue, but higher earnings than Dianthus Therapeutics. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than Phio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
47.5% of Dianthus Therapeutics shares are held by institutional investors. Comparatively, 57.3% of Phio Pharmaceuticals shares are held by institutional investors. 16.6% of Dianthus Therapeutics shares are held by company insiders. Comparatively, 0.6% of Phio Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Volatility & Risk
Dianthus Therapeutics has a beta of 1.85, indicating that its share price is 85% more volatile than the S&P 500. Comparatively, Phio Pharmaceuticals has a beta of 1.45, indicating that its share price is 45% more volatile than the S&P 500.
Summary
Dianthus Therapeutics beats Phio Pharmaceuticals on 9 of the 14 factors compared between the two stocks.
About Dianthus Therapeutics
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
About Phio Pharmaceuticals
Phio Pharmaceuticals Corp. engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells’ ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors. It is also developing PH-894, an INTASYL compound in IND enabling studies to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, effecting the immune system and the tumor. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is based in Marlborough, Massachusetts.
Receive News & Ratings for Dianthus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dianthus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.